Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The oxidative pentose phosphate pathway (PPP) is crucial for cancer cell metabolism and tumor growth. We recently reported that targeting a key oxidative PPP enzyme, 6-phosphogluconate dehydrogenase (6PGD), using our novel small-molecule 6PGD inhibitors Physcion and its derivative S3, shows anticancer effects. Notably, humans with genetic deficiency of either 6PGD or another oxidative PPP enzyme, glucose-6-phosphate dehydrogenase, exhibit non-immune hemolytic anemia upon exposure to aspirin and various antimalarial drugs. Inspired by these clinical observations, we examined the anticancer potential of combined treatment with 6PGD inhibitors and antimalarial drugs. We found that stable knockdown of 6PGD sensitizes leukemia cells to antimalarial agent dihydroartemisinin (DHA). Combined treatment with DHA and Physcion activates AMP-activated protein kinase, leading to synergistic inhibition of human leukemia cell viability. Moreover, our combined therapy synergistically attenuates tumor growth in xenograft nude mice injected with human K562 leukemia cells and cell viability of primary leukemia cells from human patients, but shows minimal toxicity to normal hematopoietic cells in mice as well as red blood cells and mononucleocytes from healthy human donors. Our findings reveal the potential for combined therapy using optimized doses of Physcion and DHA as a novel antileukemia treatment without inducing hemolysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment
Schafer, Z. T., Grassian, A. R., Song, L., Jiang, Z., Gerhart-Hines, Z., Irie, H. Y., Gao, S., Puigserver, P., & Brugge, J. S. (2009) · Nature · doi:10.1038/nature08268 · Cited by 1,031 · cited 6×
“A uthor M anuscript A uthor M anuscript Keywords Cancer metabolism; hemolytic anemia; 6-phosphogluconate dehydrogenase; anti-malarial agent; leukemia cell proliferation Introduction G6PD and 6PGD are the first and third enzymes of the oxidative PPP, which links glycolysis to anabolic biosynthesis and produces NADPH to…”
InfluentialLin, R., Elf, S., Shan, C., Kang, H.-B., Ji, Q., Zhou, L., Hitosugi, T., Zhang, L., Zhang, S., Seo, J. H., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3255 · Cited by 287
Self-citationDihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway
Wang, S.-J., Sun, B., Cheng, Z.-X., Zhou, H.-X., Gao, Y., Kong, R., Chen, H., Jiang, H.-C., Pan, S.-H., Xue, D.-B., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1643-7 · Cited by 86
Cited by
NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications
Ju, H.-Q., Lin, J.-F., Tian, T., Xie, D., & Xu, R.-H. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00326-0 · Cited by 581
Human TKTL1 implies greater neurogenesis in frontal neocortex of modern humans than Neanderthals
Pinson, A., Xing, L., Namba, T., Kalebic, N., Peters, J., Oegema, C. E., Traikov, S., Reppe, K., Riesenberg, S., Maricic, T., et al. (2022) · Science · doi:10.1126/science.abl6422 · Cited by 160
Yang, X., Peng, X., & Huang, J. (2018) · Clinical and Translational Oncology · doi:10.1007/s12094-018-1833-4 · Cited by 59
Guo, H., Xiang, Z., Zhang, Y., & Sun, D. (2019) · Clinical and Translational Oncology · doi:10.1007/s12094-018-1937-x · Cited by 34
Metadata
- Authors
- Elf, S., Lin, R., Xia, S., Pan, Y., Shan, C., Wu, S., Lonial, S., Gaddh, M., Arellano, M. L., Khoury, H. J., Khuri, F. R., Lee, B. H., Boggon, T. J., Fan, J., & Chen, J.
- Venue
- Oncogene
- Published
- 2016-06-06
- Volume
- 36
- Issue
- 2
- Pages
- 254-262
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2416096426
- Cited by
- 63
- References
- 3
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.